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Abstract 
The human promyelocytic cell line HG60 can be differentiated with retinoic acid (RA) along the granulocytic pathway. Numerous 
studies have identified many synergistic combinations of RA with cytostatics, cytokines and other inducers. A combination of FU with 
the crude thymus extract Thymex-L increased differentiation of HL-60 cells as confirmed by two functional assays and morphology, 
whereas the extract itself did not show any effect. The functional markers phagocytosis-associated chemiluminescence and nitroblue 
tetrazolium reduction were more enhanced (up to 4-fold with 1000 pg/ml Thymex-L) than morphology. The effect was found over a 
wide RA concentration range (10F”-10-6 M) and was dependent on extract concentration. The half-maximal induction of both 
functional markers was reached at 400 pg/ml. To achieve the same effect with the combination in comparison with RA alone, an R4 
dose reduction of about lOO-fold was estimated. The effect was also seen when the cells were pretreated with the thymus extract for two 
days. The enhancement of RA action by Thymex-L was not correlated with an increase of extracellular or intracellular RA concentration. 
The active compound in Thymex-L is heat stable and bigger than 5 kDa as confirmed by gelfiltration. The defined thymus peptides 
thymosin CQ, prothymosin (Ye and thymopentin were unable to synergistically enhance HL-60 differentiation. These data suggest that the 
treatment with a thymus extract can increase the sensitivity of HL-60 cells for RA. This may have clinical implications. 
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1. Introduction 
Several leukemic diseases are characterized by a break- 
down in myeloid cell maturation. To restore the normal 
differentiation such patients are treated in differentiation 
therapy [l] with agents like all-trans-retinoic acid [2,3]. 
However, remission can not be reached in all cases and the 
therapy has toxic side effects. Therefore, it seems worth- 
while to search for other substances which induce differen- 
tiation alone or in combination with well established in- 
ductors. 
Under in vitro conditions the HL-60 cell line can serve 
as a model in differentiation experiments. Originally de- 
rived from a patient with acute promyelocytic leukemia, 
the cells can be differentiated along either the granulocyte 
or the monocyte/macrophage lineage by various chemi- 
Abbreviations: LU, light units; NBT, nitroblue tetrazolium; RA, 
all-trans-retinoic acid. 
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cals (see [4] for review). The portion of induced cells can 
be evaluated by functional and by morphological parame- 
ters. 
Numerous studies have identified many synergistic 
combinations in inducing differentiation of various human 
myeloid leukaemic cell lines [5]. Combinations of RA with 
cytostatics, cytokines and other differentiation inducers are 
effective. Some of them may have an immunomodulatory 
activity. 
It is generally accepted that the thymus gland plays an 
important role in the maturation of T cells [6]. A number 
of peptides has been isolated from thymus extracts. The 
widespread occurrence of some thymic peptides like pro- 
thymosin CX~ [7] or thymosin cq [8] suggests a general 
role of these substances. Synergistic effects of both thy- 
mosin czl and prothymosin (Ye in different immunological 
systems have been described [9,10]. Effects of thymus 
extracts upon myeloid differentiation have not yet been 
reported, however. 
Here we describe the effects of the crude thymus extract 
Thymex-L and of defined thymus peptides on M-induced 
K. Schulze-Forster et al./Biochimica et Biophysics Acta 1265 (1995) 110-116 111 
HG60 differentiation. In addition to morphological inspec- 
tion, two functional tests <are employed in this study. Our 
results show that the crude thymus extract Thymex-L 
potentiates the RA effects and that the active compound is 
greater than 5 kDa. This effect is not caused by the thymic 
peptides thymosin (or, prothymosin (or, and thymopentin. 
2. Materials and methods 
2.1. Materials 
The thymus extract Thymex-L and prothymosin ~yr 
were purchased from Thymoorgan-GmbH Pharmazie, 
Vienenburg (Germany). Thymex-L is a crude water-extract 
from calf thymus containing peptides and proteins with a 
molecular mass range of’ 2-68 kDa, as determined by 
SDS-electrophoresis. An extract from lamb liver and spleen 
(AF2) was obtained from Biosyn Arzneimittel, Fellbach 
(Germany). Thymopentin was from Cilag, Schaffhausen 
(Switzerland), and all the other substances were from 
Sigma, Deisenhofen (Germany). 
2.2. Cell culture 
HL-60 cells were grown in RPM1 1640 with 10% 
inactivated fetal calf serum, penicillin (100 units/ml), and 
streptomycin (0.1 mg/ml)l. The cultures were incubated in 
humidified air at 37°C with 5% CO, and subcultivated 
twice a week. Cell viability was controlled by the trypan 
blue exclusion method. 
2.3. Induction of cell differentiation 
HG60 cells (1.25 . 10’ cells/ml) were induced to dif- 
ferentiate along the gramdocytic pathway with all-trans- 
retinoic acid at a concentration ranged from 10m6 M to 
lo-” M. Final ethanol concentration from the RA stock 
solution and dilutions were 0.1%. For differentiation in- 
duction the extracts or peptides were used alone or in 
combination with RA as indicated at the respective experi- 
ments. All experiments were performed at least twice. 
After 5 days of incubation the cells were counted. 
Viability of the cells was over 90% under these conditions. 
An aliquot of cell suspension was prepared on glas slides 
and stained with Wright-Giemsa stain for morphological 
analysis. Duplicate lOO-cells counts were performed under 
a light microscope. Morphological characterisation was 
performed as described Ipreviously [ill. The remaining 
cells were collected by centrifugation, washed once with 
PBS and examined by the chemiluminescence and NBT 
assay. 
2.4. Chemiluminescence 
The spontanous chemiluminescence of 40 ~1 cells (5 . 
lo6 cells/ml) in the presence of 100 ~1. 10e4 M luminol 
was measured with an Amerlite Analyser ZLElOO 
(Amersham). After the addition of 100 ~1 opsonized zy- 
mosan (7 mg/ml) every 3 min the luminescence was read 
over 3 h. For calculation the mean of the area under the 
curve from duplicate samples was estimated. 
2.5. Nitroblue tetrazolium (NBT) assay 
The cells were incubated for 20 min at 37°C in 1 ml 
RPM1 1640 with 1 mg/ml NBT and 100 ng/ml phorbol 
myristate acetate. 250 ~1 of the cell suspension were 
added into 3 wells of a 96-well microtitre plate. After 
addition of 50 ,ul of 25% SDS in 0.075 M NaOH the 
plates were incubated overnight at 37°C and measured in a 
SLT EAR 400 AT microtitre plate reader at 550 nm. The 
mean from the 3 wells was corrected 
number. 
for the initial cell 
2.6. Phagocytosis assay 
To measure phagocytosis using a Phagotest kit the 
instructions of the producer were followed (Orpegen, Hei- 
delberg, Germany). Briefly, 1 . lo6 cells/ml supplemented 
with 15% human serum were incubated for 10 min at 37°C 
with FITC-labeled E. coli and washed. The fluorescence 
of the cells was measured in a FACScan (Becton Dickin- 
son). 
2.7. Gel filtration 
A total of 15 mg Thymex-L in 400 ~1 PBS were 
applied to a 10 ml G25 column (PD-10, Pharmacia). 
During elution with PBS fractions of 1.5 ml were col- 
lected. 150 ~1 of each fraction were tested in the differen- 
tiation assay. Protein determinations were carried out by 
the Bradford method [12]. 
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Fig. 1. Chemiluminescence of RA-induced I-E-60 cells. The cells were 
treated for 5 days with RA alone (solid lines) or in combination with 600 
pg/ml Thymex-L (dashed lines). The RA concentrations were 10m6 M 
(01, 10m7 M (A), 10-s M (x), and without RA as control (ml. The 
arrow indicates the addition of opsonized zymosan. Luminescence was 
measured every 3 min. 
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2.8. RA quantification 
1 . lo7 HL-60 cells were washed twice with PBS, lysed 
by three cycles of freezing/thawing and centrifuged. 180 
~1 of a 1:l mixture of acetonitrile and isobutanol were 
added to 250 ~1 supematant from cell lysis or culture 
medium and vortexed. After the addition of 150 ~1 satu- 
rated K,HPO, solution and mixing, the samples were 
centrifuged and the organic layer was collected. The ex- 
traction was repeated, the organic phases were evaporated 
and redissolved in 200 ~1 mobile phase. RA was separated 
by HPLC on a C,, Spherisorb column (Kontron, 125 X 4.6 
mm) using acetonitrile:water 9:l with 20 mM ammonium 
acetate, pH 6.9 as mobile phase. Peak areas from UV 
detection at 365 nm were used for calculation of the RA 
content from a standard curve. 
3. Results 
3.1. Chemiluminescence reaction of RA-induced HL-60 
cells 
Fig. 1 shows the chemiluminescence reaction of RA-in- 
duced HL-60 cells. The cells recognize an opsonified 
particle and react by generating oxygen products measured 
via chemiluminescence. Induced cells without stimulus and 
uninduced HL-60 cells with stimulus show no light emis- 
sion. After the addition of opsonized zymosan the peak 
values amounted to about 43 light units (LU) with 10m6 M 
RA, 20 LU with lop7 M or 8 LU with lop8 M RA. The 
maximum of the curves is reached after 27 min. Also the 
area under the luminescence curve correlates with the RA 
concentration and is a suitable marker for differentiated 
HG60 cells. The presence of 600 pg/ml Thymex-L alone 
did not affect the light emission. In contrast, the combina- 
tion from Thymex-L with RA is much more effective than 
RA itself. According to Fig. 1 the kinetics of the lumines- 
cence reactions do not change, only the peak height is 
enlarged (137 LU with lop6 M RA and Thymex-L, 43 LU 
RA alone). 
3.2. Effects of various Thymex-L concentrations on differ- 
entiation of HL-60 cells 
Fig. 2 represents the correlation of the two functional 
markers chemiluminescence and NBT reaction with the 
Thymex-L concentration in the absence and presence of 
RA, respectively. All data from a typical experiment shown 
in Fig. 2 are related to the value obtained with lo-’ M RA 
as standard. It is obvious that the thymus extract alone has 
no influence on the functional markers. The morphological 
analysis (Table 1) supports this finding. In all cases about 
80% of the cells are in the promyelocytic stage. However, 
in combination with a suboptimal concentration of RA 
(lo-’ M) the extract is able to enhance the RA effects 
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Fig. 2. Effects of various Thymex-L concentrations on differentiation of 
HL-60 cells. The degree of induction was assessed by chemiluminescence 
(A) and NBT reduction (*). The cells were treated for 5 days with 
extract alone (solid lines) or with both extract and lo-* M RA (dashed 
lines). All data are related to the effects achieved with lo-’ M R4 alone 
(100%). 
(Fig. 2). Each marker differs in the degree of induction but 
both functional markers demonstrate a dose-dependency. 
Chemiluminenscence gives the strongest response up to a 
4-fold increase with 1000 pg/ml Thymex-L. In five 
experiments the mean induction with 600 pg/ml extract 
was calculated as 332.6% f 78.9. This Thymex-L-induced 
increase was significant using the Wilcoxon signed-rank 
test (P = 0.03). The NBT test is less sensitive (2-fold 
increase with 1000 pg/ml Thymex-L). The two func- 
tional markers reached their half-maximal effects at about 
400 pg/ml. By morphology a maximal 2-fold increase is 
seen at the highest Thymex-L concentration (Table 1). Not 
only the total number of mature cells but also their distri- 
bution is changed into banded and segmented granulocytes 
(4% in RA control, 55% with 1000 pg/ml + RA, 34% 
with 600 pg/ml + RA). 
Table 1 
Effects of various Thymex-L concentrations on the morphology of HL-60 
cells 
Thymex-L RA lo-’ M % of total cells 
(mg/ml) mature cells 
Pro Myelo Meta Band Seg 
0 - 84 16 0 0 0 
50 - 81 18 1 0 0 
200 - 81 17 2 0 0 
600 - 77 19 3 0 1 
1000 - 81 15 4 0 0 
0 + 64 23 9 3 1 
50 + 56 29 13 2 0 
200 + 65 27 5 1 2 
600 + 39 19 8 15 19 
1000 + 28 13 4 12 43 
HL-60 cells were cultured with the extract Thymex-L alone or with both 
extract and lo-’ M RA. Differentiation was assessed after 5 days as 
described in Section 2. Pro, Promyelocyte; Myelo, myelocyte; Meta, 
metamyelocyte; Band, banded neutrophil; Seg, segmented neutrophil. 
R Schuke-Forster et al./Biochimica et Biophysics Acta 1265 (1995) 110-116 
In parallel experiments the differentiation inductor 
DMSO was used in thre:e common concentrations (l%, 
1.3%, 1.6%) instead of RA. 1% DMSO induced a morpho- 
logical HG60 differentiation to about 80%. A synergistic 
interaction with Thymex-L was not observed (data not 
shown). 
In addition phagocytosis was examined by FACS analy- 
sis using fluorescence-labeled bacteria. In two independent 
assays a moderate increabse of phagocytes (+ 10%) was 
found among those cells which were treated with the 
combination of RA (10e6 M) and 600 pg/ml Thymex-L 
(data not shown). The number of phagocytic cells in the 
group treated only with Thymex-L was found in the range 
of the untreated control. 
3.3. Effects of Thymex-L on RA-induced HL-60 differentia- 
tion at different RA-concentrations 
The Thymex-L-induce:d increase was investigated at 
different RA concentrations (10-“-10-6 M) using a fixed 
extract concentration (600 pg/ml) by the three different 
differentiation markers. Chemiluminescence measurements 
show the greatest effect (Fig. 3) even at a high RA 
concentration (10m6 M), at which 90% of the cells are 
morphologically mature with RA alone. Below 10P1’ M 
RA the increase is less than 2-fold. In the same manner the 
NBT test is influenced. Morphology shows a relatively 
constant increase over the whole range except for 10e6 M 
RA. Looking at the percentage of banded and segmented 
neutrophils in the range: over lo-’ M RA a greater 
increase can be seen in this group (e.g., at 10m7 M RA 
lo-fold) than in the total number of differentiated cells 
(1.2-fold). 
Regarding the effect at lop6 M RA alone, Fig. 3 shows 
that the same effect can 'be achieved with less RA if the 
combination with Thymex-L was used. As deduced from 
chemiluminescence measurement only 1% RA is suffi- 
cient. By the NBT reaction 0.1% RA gives the same effect 
and by morphology only 10% are necessary. The RA 
concentration needed to induce half-maximal morphologi- 
cal differentiation can be reduced from 10e8 M RA (48% 
mature cells) to lo- ” k4 RA in the combination (53% 
mature cells). 
3.4. Effects of thymic peptides 
In order to test the involvement of thymic peptides, 
thymosin cq, prothymosin q, and thymopentin were used 
in the differentiation assay. The peptides (200 ng/ml) 
were given alone and together at two different RA concen- 
trations (lop7 and lo-’ M RA). None of the factors 
increases the spontaneous differentiation rate (values with- 
out RA) and none is efficient in the presence of RA 
compared to Thymex-L (data not shown). For control the 
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Fig. 3. Effects of Thymex-L on RA-induced differentiation of HL-60 
cells at different RA concentrations. The cells were treated with the 
indicated RA concentration alone (solid lines) or in combination with 600 
pg/ml Thymex-L (dashed lines). (A) Area under the chemiluminescence 
curve. (B) NBT reduction. (Cl Percentage of differentiated cells beyond 
the promyelocytic stage (W 1, percentage of banded and segmented cells 
(0). 
commercially available extract AF2 (from lamb liver and 
spleen) and bovine serum albumin were used. They were 
found to be ineffective in this assay. 
114 K. Schulze-Forster et al./Biochimica et Biophysics Acta 1265 (1995) 110-116 
??chemiluminescence ??morphology 
60 
P 
50 - 
r 
8 
40 ; 
5 
30 El 
$ 
+ 
P 
20 E 
2 
10 
0 
RAP4 104 104 10.’ lo* 108 104 104 104 
Thymex-Lpetreatment - - - - + + + + 
mymex-L in 
mainincubation - - ++ -- ++ 
Fig. 4. Effects of Thymex-L pretreatment on F&induced differentiation 
of HL-60 cells. The cells were preincubated with 600 pg/ml thymus 
extract for 48 h and washed prior to incubation with RA. The degree of 
differentiation was assessed by chemiluminescence (black bars) and the 
number of banded and segmented neutrophils (white bars). 
3.5. Effects of Thymex-L pretreatment on RA-induced HL- 
60 differentiation 
To further understand the mechanism of potentiation of 
PA-induced differentiation by thymic extracts, the effect 
of cell pretreatment was examined. The cells were preincu- 
bated for 48 h with 600 pg/ml Thymex-L and washed 
before RA induction. By chemiluminescence (Fig. 4) the 
pretreated cells show the same stimulation as the cells 
which are treated simultaneously with RA and Thymex-L 
(at low6 M RA: 2-3-fold). When the extract is present 
during preincubation and main incubation, an enhancement 
greater than 5-fold takes place. In the morphological devel- 
opment the preincubated cells do not completely reach the 
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Fig. 5. Gelfiltration of Thymex-L on G25. 400 ~1 diluted extract were 
applied to a G25 column and eluated with PBS. The absorbance at 280 
nm was measured continously (solid line). The fractions indicated by 
solid bars were tested for inducing differentiation in combination with 
10m8 M RA. The dashed line gives the values from the chemilumines- 
cence assay related to the effects achieved with RA alone (100%). 
Table 2 
Influence of Thymex-L on RA concentrations 
Without Thymex-L With Thymex-L 
Extracellular RA concentration 92.6 83.7 
(ng/ml medium) 100.4 95.0 
Intracellular RA concentration 5.4 5.2 
(ng/lO’ cells) 5.1 5.3 
HL-60 cells were cultured with 10m6 M FU in the absence or presence of 
600 pg/ml Thymex-L. After 27 h RA was extracted from both medium 
and cell lysate. The RA content was determined by HPLC analysis. The 
values obtained from two independent extractions are given. 
number of banded and segmented cells (8% instead of 
ll%, 1O-8 M PA), but the number of these cells is also 
the highest with Thymex-L in both incubations (28%). 
These results suggest that the thymus extract primes the 
cells before RA acts. 
3.6. Determination of RA concentrations 
With a sensitive and specific HPLC-based method the 
intracellular and extracellular PA concentrations were esti- 
mated. As little as 1 ng per ml could be detected, extracts 
of cells without RA treatment showed no peaks. After 27 h 
of incubation with RA (10m6 M, 300 ng/ml) no signifi- 
cant differences between samples with or without Thymex- 
L were seen (Table 2). This is true of the extracellular 
(medium) as well as the intracellular RA content. Similar 
data were obtained after a 4 h RA incubation (not shown). 
3.7. Characterisation of active compounds in Thymex-L 
Thymex-L was fractionated on a G25 gelfiltration col- 
umn. The absorption profile (280 nm) shows two main 
peaks: The first eluates in the void volume (fraction 2) and 
the second, larger peak represents the small molecules 
(Fig. 5). An aliquot of each fraction was tested in the 
differentiation assay in combination with lOpa M RA. 
Only fraction 2 representing the compounds greater than 5 
kDa was active. With a final protein concentration in the 
assay of 25 ,ug/ml a chemiluminescence enhancement of 
about 180% was reached. 
Additionally, the extract was incubated in a boiling 
water bath for 10 mitt, denaturated proteins were removed 
by centrifugation and aliquots of the clear supematant 
were added into the differentiation assay. In several experi- 
ments the heat-inactivated extract maintained the synergis- 
tic effect with RA on HL-60 cells (data not shown). 
4. Discussion 
Here we show, that the crude aqueous thymus extract 
Thymex-L significantly enhances the differentiation of 
HL-60 cells induced by RA. In this respect the three 
investigated differentiation markers and the phagocytosis 
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assay verify this result. Substances enhancing the w-in- 
duced differentiating effect can be divided into 2 groups: 
Chemicals like sodium butyrate or hexamethylene bisac- 
etamide inducing HL-60 cell differentiation alone; together 
with FU these substances act synergistically 1131. In addi- 
tion, triple combinations @A/6-thioguanine/hexamethy- 
lene bisacetamide) were explored [14]. On the other hand, 
agents like Sphinganine am known to lack their own effect 
on HL-60 differentiation but increased the RA-induced 
differentiation [15]. From our results it seems that 
Thymex-L belongs to the second group. 
The different degree of influence on the differentiation 
markers is striking. It was found that the presence of 
Thymex-L increases only moderately the percentage of 
cells with differentiated morphology, but it has a strong 
effect on the functional competence. However, the portion 
of cells in the different stages of maturation is altered. 
Thymex-L increases the number of highly differentiated 
cells (banded and segmented neutrophils) more than the 
percentage of cells beyond the promyelocytic stage. Com- 
paring the two functional markers chemiluminescence is 
more sensitive to Thymex-L than the NBT reaction. 
Whereas phorbol ester-stimulated superoxide production 
(NBT assay) requires only a functional NADPH oxidase, 
the response to opsonized zymosan entails the presence of 
complement receptors and the coupling mechanisms to the 
oxidase. 
The extent of morphollogical differentiation with 10m6 
M RA was found in the range described by other groups 
[15,16]. Interestingly, although about 90% of the cells were 
already classified as mature by morphology after induction 
by lop6 M RA alone, the strong activation of chemilumi- 
nescence induced by the addition of Thymex-L is main- 
tained. If these cells were completely differentiated and 
contain the normal functional enzyme activity of granulo- 
cytes, it should not be possible to enhance the chemilumi- 
nescence. Previous studie:s suggest that induced granulo- 
cytic differentiation of HL-60 is incomplete and defective. 
For example induced cellos lack lactoferrin [17] and were 
found to be deficient in their enzyme equipment [18]. Our 
results indicate that the Imorphologically mature RA-in- 
duced cells have not the full reactivity and that the thymus 
extract may have a restoring effect. 
The cellular mechanism of the Thymex-L-induced 
potentiation of RA effects is not known. The results from 
pretreatment experiments demonstrate that the thymus ex- 
tract modulates the cells before RA acts. It was found that 
HL-60 cells are highly sen.sitive to RA at the G,/S phase. 
Thus Sphinganine blocks the cells at this point of the cell 
cycle and enhances the number of morphological mature 
cells after RA induction [l-9]. We observed only a moder- 
ate influence on morphology and a strong increase of the 
respiratory burst. Therefom, the mechanism may be differ- 
ent. Interestingly, using DIMS0 as granulocytic inducer no 
Thymex-L action was detected, suggesting a specific ac- 
tion in the RA pathway. From our experiments we can 
exclude that higher RA concentrations in extract-treated 
cells were responsible for the effects. For maximal induc- 
tion the presence of RA is necessary within the first 24 h 
[16]. During this period changes between treated and un- 
treated cells were not detected. Because the biological 
effects of RA are mediated by retinoic acid receptors [20], 
an influence at this level is imaginable. 
However, comparing the effects of the total thymus 
extract Thymex-L with respect to the peptides thymosin 
cyi, prothymosin (pi, and thymopentin which are active in 
various immunological test systems [21-231, these pep- 
tides were ineffective in our assays. Therefore, an un- 
known component or the presence of several thymus fac- 
tors together may be responsible for the effect on HL-60 
differentiation. First results on the nature of the active 
principle suggest a class of heat-stable molecules with a 
molecular mass over 5 kDa. Consequently low molecular 
mass compounds (e.g., hormones) seems to be not respon- 
sible for the effect. The specific activity of this compound 
can be increased by purification using gelfiltration. There- 
fore, a dosis reduction is possible which is important for 
therapeutical use. Further studies must elucidate this fact. 
Our results may have some clinical relevance. The 
advantages of a combination therapy are reduction of dose, 
toxicity, and overcome of resistance. For the functional 
markers and the RA concentration which induces 50% of 
morphological differentiation, an extreme m-dose reduc- 
tion of lOO-fold and more was estimated. In general other 
authors have described reduction factors less than 25 [5,13]. 
Therapeutic experiences over ten years with Thymex-L, 
which is a licensed drug in Sweden, have clearly shown 
that undesired immunological reactions are not seen by 
long-term treatment. Based on the presented data, we 
suggest further investigations to elucidate the role of thymic 
extracts in the differentiation therapy of leukemic diseases. 
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